Global Initiative for Psychedelic Science Economics (GIPSE)
GIPSE is a network of health economists dedicated to achieving the potential of psychedelic therapies for high-priority mental health conditions. Through the application of policy-relevant economic analyses, GIPSE seeks to enhance clinical outcomes, increase efficiency of service delivery, and increase access to these promising therapies for everyone who can benefit. Below is a list of current projects:
- In collaboration with the Usona Institute, modeling the cost-effectiveness of psilocybin-assisted psychotherapy to treat major depressive disorders.
- In collaboration with the Multidisciplinary Association for Psychedelic Studies (MAPS), evaluating the cost-effectiveness of MDMA-assisted therapy for people with chronic PTSD.
- In collaboration with Johns Hopkins University’s Center for Psychedelic and Consciousness Research, evaluating the cost-effectiveness of psilocybin-assisted therapy for smoking cessation.
- Modeling the short and long-term epidemiological, economic, and budgetary impacts of scaled-up access to psychedelic therapies at the state and national level.
This two-page summary provides additional information on GIPSE’s mission and activities.
- Rick Doblin, Executive Director, Multidisciplinary Association for Psychedelic Studies (MAPS)
- Matthew Johnson, Associate Center Director, Johns Hopkins University, Center for Psychedelics & Consciousness Research
- Tura Patterson, Senior Director, Strategic partnerships, Usona Institute
- Eduardo Schenberg, Founder, Instituto Phaneros (São Paolo, Brazil)